| Objective To investigate the effect of alendronate on bone metabolism and bone mineral density (BMD) in postmenopausal women with type 2 diabetes and osteoporosis. Methods Fifty-one postmenopausal women with type 2 diabetes and osteoporosis, who received treatment in our hospital from Janaury 2012 to Janaury 2013, were selected. All the patients were treated with alendronate for 6 months. BMD of L2-L4 and the left proximal femur (including the neck, the Torch, and the Ward’s triangle) was detected using dual energy X-ray absorptiometry (DEXA, Norland, USA). The height, weight, FBG, HbAlc, PTH, OC, CTX, 25(OH)VD, and BALP were also detected. The changes of BMD and bone metabolic markers before and after treatment were compared. Results In these postmenopausal women with type 2 diabetes and osteoporosis, after 6-month alendronate treatment, FBG, 2hPG and HbA1c were significantly lower than those before the treatment（P<0.05）. The serum levels of Ca and P before the treatment had no significant difference with that after the treatment(P>0.05). The serum CTX level after the treatment was significant lower than that before the treatment（P<0.05）. The serum levels of OC, PTH, BALP, and 25OHVD after the treatment had no significant difference with those before the treatment(P>0.05). BMD of L2, L3, L4, L2-4, the femoral neck after the treatment were significantly higher than that before the treatment（P<0.05）. BMD of the Torch and the Ward's triangle after the treatment had no significant difference with that before the treatment(P>0.05). Conclusion The efficacy of alendronate on osteoporosis in postmenopausal with type 2 diabetes is obvious, which can improve the bone metabolic markers and BMD in a short time. |